Program
Anti-TA-MUC1/DXd Antibody-drug Conjugate DS-3939a
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by Daiichi Sankyo.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 22 open or running | phase 2since May 10, 2023 | May 10, 2023 | Aug 11, 2028phase 2 · NCT05875168 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 10, 2023First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05875168 · 590 planned · United States, Belgium, Canada and more
- Jul 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966 · 400 planned · United States, Argentina, Austria and more
- Oct 15, 2026Primary completion moved from 2026-10-20 to 2028-08-11Date moved laterphase 2 · +22 months · NCT05875168
Ahead
- Aug 11, 2028Primary completion: phase 2 study in Neoplasm MetastasisNCT05875168
- Jul 31, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07739966Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 2 | Recruiting | Jul 31, 2030 | 400 |
| NCT05875168Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Recruiting | Aug 11, 2028 | 590 |
How it is read
Names in the registry
- “DS-3939a”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.